PMC10226363_01
Case 1. Continuous glucose monitoring metrics during use of rapid-acting insulin analogue and during use of Fiasp
PEDM-27-46173-g001.jpg
PMC10226363_01_PEDM-27-46173-g001.jpg
F1
TIR and TAR (time above range: > 180 mg/dl) and CV (Fig. 1). The patient was satisfied with the shorter waiting time between prandial bolus and start of the meal.
PMC10226363_02
Case 2. Postprandial glucose after breakfast during use of rapid-acting insulin analog (A) and during use of Fiasp (B)
PEDM-27-46173-g002.jpg
PMC10226363_02_PEDM-27-46173-g002.jpg
F2
CGM metrics showed similar results: a mean glycemia of 116 +-39 mg/dl, TIR - 83%, CV - 33.4%, however much lower prandial glucose after the breakfast was noted (Fig. 2).